JP2006521807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006521807A5 JP2006521807A5 JP2006506517A JP2006506517A JP2006521807A5 JP 2006521807 A5 JP2006521807 A5 JP 2006521807A5 JP 2006506517 A JP2006506517 A JP 2006506517A JP 2006506517 A JP2006506517 A JP 2006506517A JP 2006521807 A5 JP2006521807 A5 JP 2006521807A5
- Authority
- JP
- Japan
- Prior art keywords
- positive
- cells
- nestin
- ncam
- neural progenitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 71
- 238000000034 method Methods 0.000 claims description 49
- 102000008730 Nestin Human genes 0.000 claims description 37
- 108010088225 Nestin Proteins 0.000 claims description 37
- 210000005055 nestin Anatomy 0.000 claims description 37
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 29
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 29
- 210000005155 neural progenitor cell Anatomy 0.000 claims description 25
- 239000002609 medium Substances 0.000 claims description 22
- 230000004069 differentiation Effects 0.000 claims description 16
- 210000005064 dopaminergic neuron Anatomy 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 10
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 10
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 10
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 10
- 102000003693 Hedgehog Proteins Human genes 0.000 claims description 10
- 108090000031 Hedgehog Proteins Proteins 0.000 claims description 10
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 10
- 210000002242 embryoid body Anatomy 0.000 claims description 10
- 230000001537 neural effect Effects 0.000 claims description 10
- 210000002569 neuron Anatomy 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 9
- 102000004877 Insulin Human genes 0.000 claims description 8
- 108090001061 Insulin Proteins 0.000 claims description 8
- 102000004338 Transferrin Human genes 0.000 claims description 8
- 108090000901 Transferrin Proteins 0.000 claims description 8
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 8
- 229960001471 sodium selenite Drugs 0.000 claims description 8
- 235000015921 sodium selenite Nutrition 0.000 claims description 8
- 239000011781 sodium selenite Substances 0.000 claims description 8
- 239000012581 transferrin Substances 0.000 claims description 8
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 7
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 claims description 7
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims description 7
- 229960004308 acetylcysteine Drugs 0.000 claims description 7
- 230000000862 serotonergic effect Effects 0.000 claims description 7
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 claims description 6
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 claims description 6
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 6
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 6
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 6
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims description 5
- 102100037362 Fibronectin Human genes 0.000 claims description 5
- 108010067306 Fibronectins Proteins 0.000 claims description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 239000007640 basal medium Substances 0.000 claims description 4
- -1 B27 Substances 0.000 claims description 3
- 239000005700 Putrescine Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960003387 progesterone Drugs 0.000 claims description 3
- 239000000186 progesterone Substances 0.000 claims description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 2
- CJGYSWNGNKCJSB-YVLZZHOMSA-M [(4ar,6r,7r,7ar)-6-[6-(butanoylamino)purin-9-yl]-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl] butanoate Chemical compound C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-M 0.000 claims description 2
- 239000012894 fetal calf serum Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 210000004248 oligodendroglia Anatomy 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000012679 serum free medium Substances 0.000 claims 10
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 7
- 241000288906 Primates Species 0.000 claims 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims 2
- 238000000608 laser ablation Methods 0.000 claims 2
- 210000003061 neural cell Anatomy 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 229960003638 dopamine Drugs 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- 102000016776 Midkine Human genes 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- 101100175316 Mus musculus Gdf5 gene Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102000004230 Neurotrophin 3 Human genes 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
- 229960005263 bucladesine Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 229940032018 neurotrophin 3 Drugs 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN269MU2003 | 2003-03-12 | ||
| IN269/MUM/2003 | 2003-03-12 | ||
| US52004803P | 2003-11-14 | 2003-11-14 | |
| US60/520,048 | 2003-11-14 | ||
| PCT/IB2004/001246 WO2004081172A2 (en) | 2003-03-12 | 2004-03-11 | Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010035457A Division JP2010187669A (ja) | 2003-03-12 | 2010-02-19 | ヒト胚幹細胞由来の最終分化ドーパミン作動性神経細胞の誘導 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006521807A JP2006521807A (ja) | 2006-09-28 |
| JP2006521807A5 true JP2006521807A5 (enExample) | 2010-04-08 |
| JP4900587B2 JP4900587B2 (ja) | 2012-03-21 |
Family
ID=34074054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006506517A Expired - Fee Related JP4900587B2 (ja) | 2003-03-12 | 2004-03-11 | ヒト胚幹細胞由来の最終分化ドーパミン作動性神経細胞の誘導 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP4900587B2 (enExample) |
| CN (1) | CN1894401B (enExample) |
| ZA (1) | ZA200401646B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009148170A1 (ja) * | 2008-06-06 | 2009-12-10 | 独立行政法人理化学研究所 | 幹細胞の培養方法 |
| EP2356450B1 (en) * | 2008-10-24 | 2019-02-06 | B.R.A.H.M.S GmbH | Prognosis and risk assessment in stroke patients by determining the level of marker peptides |
| CN101824399B (zh) * | 2009-03-05 | 2012-05-30 | 中日友好医院 | 从人羊膜上皮细胞中诱导分化出多巴胺能神经元的方法及分离所得神经元的用途 |
| CN101824398B (zh) * | 2009-03-05 | 2012-08-08 | 中日友好医院 | 人羊膜上皮细胞与神经干细胞共培养诱导分化多巴胺能神经元的方法 |
| WO2011055855A1 (en) | 2009-11-05 | 2011-05-12 | Riken | A method for differentiation induction in cultured stem cells |
| WO2011108766A1 (en) * | 2010-03-03 | 2011-09-09 | Kyoto University | METHOD FOR DIAGNOSING A PROTEIN MISFOLDING DISEASE USING NERVE CELLS DERIVED FROM iPS CELLS |
| CN110684734A (zh) * | 2011-11-04 | 2020-01-14 | 纪念斯隆-凯特琳癌症中心 | 用于植入的中脑多巴胺（da）神经元 |
| KR102073111B1 (ko) * | 2012-10-16 | 2020-02-04 | 메르츠 파마 게엠베하 운트 코. 카가아 | 신경독소 폴리펩티드의 생물학적 활성의 결정을 위한 세포 테스트 시스템 |
| SG11201601720RA (en) * | 2013-09-05 | 2016-04-28 | Univ Kyoto | New method for inducing dopamine-producing neural precursor cells |
| ES2972541T3 (es) * | 2014-09-08 | 2024-06-13 | Riken | Método para producir tejido progenitor cerebeloso |
| CN105087475B (zh) * | 2015-09-17 | 2018-12-04 | 广州赛莱拉干细胞科技股份有限公司 | 一种细胞培养液及其应用以及诱导牙髓干细胞向神经样细胞分化的方法 |
| JP2018529389A (ja) * | 2015-10-08 | 2018-10-11 | ニューロナ セラピューティクス インコーポレイテッドＮｅｕｒｏｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 神経前駆細胞集団およびそれらの使用 |
| US11898163B2 (en) | 2016-04-22 | 2024-02-13 | Kyoto University | Method for producing dopaminergic neuron progenitor cell |
| FR3058892B1 (fr) * | 2016-11-23 | 2021-04-09 | Univ Bordeaux | Unite de tissu neural et utilisation d'une telle unite pour l'implantation dans le systeme nerveux d'un mammifere |
| EP3551748B1 (en) * | 2016-12-12 | 2022-07-13 | Health and Biotech France (H&B France) | Perinatal tissue derived mesenchymal stem cells: method of preparation and uses thereof |
| WO2020054647A1 (ja) * | 2018-09-14 | 2020-03-19 | 学校法人慶應義塾 | アストロサイトの製造方法 |
| CN111304167B (zh) * | 2018-12-12 | 2024-03-26 | 上海泉眼生物科技有限公司 | 人源脂肪干细胞来源的神经元前体细胞及其制备方法和应用 |
| JP7209850B2 (ja) * | 2019-01-22 | 2023-01-20 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | 直接細胞転換に基づく神経幹細胞の星状膠細胞への分化方法 |
| CN114606188A (zh) * | 2019-03-06 | 2022-06-10 | 安徽中盛溯源生物科技有限公司 | 一种中脑多巴胺能神经前体细胞的制备方法及其应用 |
| CN110257332A (zh) * | 2019-07-08 | 2019-09-20 | 广东省赛莱拉干细胞研究院 | 一种诱导间充质干细胞分化成为多巴胺能神经元的培养基以及方法 |
| CN110669143B (zh) * | 2019-10-10 | 2021-05-14 | 中国人民解放军军事科学院军事医学研究院 | 一种短肽及其应用 |
| CN114657119B (zh) * | 2022-03-16 | 2023-10-20 | 广东省农业科学院动物科学研究所 | 一种初生仔猪肠神经胶质细胞的分离和原代培养方法 |
| CN115591025B (zh) * | 2022-11-09 | 2024-01-02 | 深圳先进技术研究院 | 神经调控器件、制备方法及其应用 |
| JP2025539432A (ja) | 2022-12-02 | 2025-12-05 | ナウェーセル バイオテクノロジーズ カンパニー リミテッド | 中脳ドーパミン作動性前駆細胞を成熟させるための培養培地、コーティングマトリックスおよび方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277820B1 (en) * | 1998-04-09 | 2001-08-21 | Genentech, Inc. | Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells |
| US7250294B2 (en) * | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
| AU2001263199B2 (en) * | 2000-05-17 | 2004-09-16 | Asterias Biotherapeutics, Inc. | Neural progenitor cell populations |
| US20030036195A1 (en) * | 2001-04-20 | 2003-02-20 | Lorenz Studer | Generation of differentiated tissue from nuclear transfer embryonic stem cells and methods of use |
-
2004
- 2004-03-01 ZA ZA200401646A patent/ZA200401646B/xx unknown
- 2004-03-11 JP JP2006506517A patent/JP4900587B2/ja not_active Expired - Fee Related
- 2004-03-11 CN CN2004800127488A patent/CN1894401B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006521807A5 (enExample) | ||
| EP2470645B1 (en) | Substantially pure human retinal progenitor, forebrain progenitor, and retinal pigment epithelium cell cultures and methods of making the same | |
| Li | Zhang, l | |
| KR100763477B1 (ko) | 사람 배아 줄기세포로부터 최종적으로 분화된 도파민작용성 뉴런의 유도 | |
| US8597945B2 (en) | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells | |
| JP4900587B2 (ja) | ヒト胚幹細胞由来の最終分化ドーパミン作動性神経細胞の誘導 | |
| US20040247571A1 (en) | Neural cells expressing tyrosine hydroxylase | |
| WO2003104444A1 (en) | Generation of neural stem cells from undifferentiated human embryonic stem cells | |
| WO2011144901A1 (en) | Expansion and directed differentiation of epidermal neural crest stem cells | |
| KR101254554B1 (ko) | 배아 줄기 세포로부터 ｇａｂａ성 뉴런의 시험관 내 생성및 신경 질환의 치료에서 그들의 사용 | |
| US8927276B2 (en) | Ex vivo progenitor and stem cell expansion and differentiation for use in the treatment of disease of the nervous system | |
| KR101613677B1 (ko) | 줄기 세포의 신경 전구 세포로의 분화용 조성물 및 이를 이용한 방법 | |
| WO2006100088A1 (en) | Neural stem cells | |
| IL177672A (en) | Dopaminergic neurons derived from corneal limbus, methods of isolation and uses thereof | |
| US8187875B2 (en) | Dopaminergic neurons derived from corneal limbus, methods of isolation and uses thereof | |
| EP1179046B1 (en) | Lineage-restricted precursor cells isolated from mouse neural tube and mouse embryonic stem cells | |
| CN118147072A (zh) | 一种诱导人多能干细胞分化为多巴胺能神经前体细胞的培养基及多巴胺能神经前体细胞的制备方法与应用 | |
| AU765517B2 (en) | Lineage-restricted precursor cells isolated from mouse neural tube and mouse embryonic stem cells | |
| Umur et al. | The Differentiation of Neuronal Cells from Mouse Embryonic Stem Cells | |
| Tabar et al. | Embryonic Stem Cells for Grafting in Parkinson's Disease | |
| Mak et al. | High Efficiency of Neural Induction in Parkinson’s Disease-Specific Induced Pluripotent Stem Cells | |
| Offen et al. | Stem Cells as a Source for Cell Replacement | |
| AU2006235917A1 (en) | Dopaminergic neurons derived from corneal limbus, methods of isolation and uses thereof | |
| Bentz | Brain Microenvironment and its Influence on Gene Expression and Differentiation of Murine Embryonic Stem Cells. Implications for Cell Replacement Strategies | |
| HK1093755A1 (zh) | 使间充质干细胞分化成神经细胞的方法 |